当前，乳腺癌已成为威胁中国女性生命健康的最大杀手，并且发病率还在逐年升高。早发现、早诊断并接受及时的治疗，对于改善乳腺癌患者的治疗效果、减少患者的经济负担和国家的卫生支出具有重要的意义。通过介绍郝希山院士团队多年来围绕乳腺癌的早诊早治探索关键技术的优化和应用，展示构建适合中国的乳腺癌早诊早治体系所取得的成果。
Breast cancer is the leading killer to Chinese women, and the incidence is still rising. Early diagnosis and treatment is of great significance to improve the patients' care, reduce the economic burden of patients and the national health care spending. This paper mainly introduces the achievements of Professor Hao Xishan's team in building the early diagnosis and treatment system of breast cancer.
[1] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
[2] World Health Organization. Data visualization tools for exploring the global cancer burden in 2020[EB/OL]. (2021-02-04)[2021-04-28]. https://gco.iarc.fr/today/online-analysis-pie?v=2020&mode=cancer&mode_population=continents&population=900&populations=160&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=7&group_cancer=1&include_nmsc=1&include_nmsc_other=1&half_pie=0&donut=0#collapsegroup-0-3
[3] 世界卫生组织. 关于癌症的10个事实[EB/OL]. (2013-01-01)[2019-09-17]. https://www.who.int/features/factfiles/cancer/facts/zh/index7.html.
[4] Jia M, Zheng R, Zhang S, et al. Female breast cancer incidence and mortality in 2011, China[J]. Journal of Thoracic Disease, 2015, 7(7):1221.
[5] Zuo T T, Zheng R S, Zeng H M, et al. Female breast cancer incidence and mortality in China, 2013[J]. Thorac Cancer, 2017, 8(3):214-218.
[6] 郝希山, 佟仲生, 陈可欣, 等. 中国女性乳腺癌筛查指南[J]. 中国肿瘤临床, 2019, 46(9):429-431.
[7] Corradini S, Reitz D, Pazos M, et al. Mastectomy or breast-conserving therapy for early breast cancer in reallife clinical practice:outcome comparison of 7565 cases. cancers (basel), 2019, 11(2):160.
[8] Mu L, Liu Y, Xiao M, et al. No association between triple-negative breast cancer and prognosis of patients receiving breast-conserving treatment[J]. Oncology Letters, 2017, 14(6):7862-7872
[9] Lu C, Xu H, Chen X, et al. Irradiation after surgery for breast cancer patients with primary tumours and one to three positive axillary lymph nodes:yes or no?[J]. Currure Oncology, 2013, 20(6):585-592.
